Products & Services
CMC Development
Peptide NCEs
Oligonucleotide NCEs
Commercial API
Commercial NCEs
Commercial Generics
Research & Specialties
Catalog Peptides
Custom Peptide Synthesis
Amino Acid Derivatives
Diagnostics
Cosmetic Peptides
Services & Capabilities
Project Management
Quality & Regulatory
Analytical capabilities
GMP Production
Research Grade Production
Supply & vertical integration
About Bachem
Company overview
Our Purpose
Our vision & strategy
Our Leadership
Our History
Our Locations
Innovation
Innovation matters
Innovation collaborations
Sustainability
People & culture
Safeguarding the environment
Acting ethically
Investors & Media
Reports & Presentations
Financial events
Media Library
Press archive
News & Events
News
Events
Careers
Contact
Select Page
Results of the capital increase
May 08, 2019
Only available in the German version.
Download
←
Peptide Trends April 2019
Peptide Trends May 2019
→
Search for:
Bachem’s liraglutide: a high-purity generic for diabetes and weight loss
Certified and essential: our peptides for in vitro diagnostics
Excellent results for the first half-year 2021
Propofol – A Bachem success story
Bachem and Novo Nordisk redesign SPPS for green chemistry
The weight loss drug Liraglutide
Interview with Amy Zhang, Head of Supply Chain at Luye Pharma
What are oligonucleotides?
Somatostatin Analogues Provide Invaluable Therapeutic Options
What are somatostatin and somatostatin analogues?
Bachem innovating through virtual events
Meet Bachem: Pascal Hess, Group Leader Generics – Portfolio
A world market leader from the Basel region – Bachem celebrates 50 years of company history
What are Amino Acids?
Bachem recognized as a winner at the Swiss Biotech Success Stories Awards 2021
What is GMP?
Will Targeting Alpha-Synuclein Lead to Treatments for Parkinson’s Disease?
Meet Bachem: Swetlana Meinhardt, Category Manager
Peptides unlock doors to understand Parkinson’s disease
Interview with Robert Yu, CEO of Yuyu Pharma
